Dr. Andrew C. von Eschenbach, named the temporary head of the Food and Drug Administration, says the agency needs to focus on emerging discoveries on the mechanisms of disease that may lead to new treatments.

President Bush appointed von Eschenbach following the surprise resignation of Commissioner Lester Crawford Friday

Food and Drug Administration (FDA) Commissioner, Dr. Lester Crawford, has resigned, after repeated claims that he allowed his agency to "play politics" with drug approvals, and oversaw some very high profile drug safety recalls.

The White House quickly named Andrew von Eschenbach, the director of the National Cancer Institute, as acting FDA commissioner

Food and Drug Administration (FDA) Commissioner, Dr. Lester Crawford, has resigned, after repeated claims that he allowed his agency to "play politics" with drug approvals, and oversaw some very high profile drug safety recalls.

The White House quickly named Andrew von Eschenbach, the director of the National Cancer Institute, as acting FDA commissioner

The Food and Drug Administration tentatively approves the manufacturing of silicone breast implants by Inamed Corp.

The move brings the company closer to returning the implants to the market years after they were banned

The U.S. Food and Drug Administration says warnings to drug companies regarding misleading advertisements have more than tripled in the last year.

Thomas Abrams, head of FDA's Division of Drug Marketing and Communications says, the agency sent 17 warning letters in the 12 months ending in August compared with an average of about four to five letters in recent years